Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis
Olmo Martín-Cámara(Universidad Complutense de Madrid), J. Carlos Menéndez(Universidad Complutense de Madrid), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Ángeles Martín‐Requero(Centro de Investigación Biomédica en Red), Geoffrey Wells, Isabel Lastres‐Becker(Biomedical Research Networking Center on Neurodegenerative Diseases), Marina Arribas(Instituto de Investigaciones Biomédicas Sols-Morreale), Giorgio Giorgi(Universidad Complutense de Madrid), Gracia Porras(Centro de Investigaciones Biológicas Margarita Salas), Pilar López‐Alvarado(Universidad Complutense de Madrid), Marcos Morales-Tenorio(Centro de Investigaciones Biológicas Margarita Salas)
Cited by 22
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
Transcription Factors NRF2 and NF-κB Are Coordinated Effectors of the Rho Family, GTP-binding Protein RAC1 during Inflammation
|Journal of Biological Chemistry|2014|314